Natrecor brain natriuretic peptide data

SCIO (Mountain View, Calif.) reported Phase I/II findings that a bolus injection of Natrecor resulted in statistically significant improvements in cardiac function that were dose-dependent.

The four doses tested in the 24 patients were 0.3, 1.0, 3.0, and 10 ug/kg, or placebo, and were monitored for four hours. The two highest doses were associated with significantly improved vascular resistance, cardiac index, and several other cardiovascular measures (p<0.05). Mean arterial pressures declined with the two highest doses but the change was not symptomatic, the company said. ...